For individuals who've plateaued on tirzepatide or semaglutide, quite possibly the most evidence-primarily based following move in 2026 is optimizing the current protocol. Adjusting dose timing, revisiting macronutrient distribution, or incorporating resistance education to protect lean mass all through ongoing weight loss. Alongside one another